Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials

Tang, Huilin; Zhang, Xi; Zhang, Jingjing; Li, Yufeng; Gobbo, Liana C Del; Zhai, Suodi; Song, Yiqing

doi:10.1007/s00125-016-4101-6

Cited by 110 publications

(118 citation statements)

References 28 publications

(30 reference statements)

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…17 Newer antidiabetic agent, sodium-glucose co-transporter 2 (SGLT2) inhibitors have been reported to increase serum Mg level in diabetic patients. 25 Most studies related to serum Mg and diabetes were done among diagnosed diabetic patients. Half of type 2 diabetic patients remain undetected and one-third to half of type 2 diabetic patients have one or more complications during diabetes diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Serum Magnesium Level of Newly Detected Patients with Glucose Intolerance and Its Comparison with Serum Magnesium Level of Age and Sex Matched Healthy Volunteers

Rahim

Mitra

2018

J. Medicine

View full text Add to dashboard Cite

Abstract Abstract Abstract Background: Background: Background: Background: Background: Hypomagnesaemia is associated with insulin resistance, diabetes mellitus (DM) and diabetic complications. Diabetic patients, on the other hand, often have low magnesium levels. This study was designed to evaluate serum magnesium level of patients with new diagnosis of any level of glucose intolerance e.g. impaired fasting glucose, impaired glucose tolerance (IGT) or DM and to compare these with serum magnesium level of age and sex matched healthy controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Magnesium Level of Newly Detected Patients with Glucose Intolerance and Its Comparison with Serum Magnesium Level of Age and Sex Matched Healthy Volunteers

Rahim

Mitra

2018

J. Medicine

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that serum magnesium (Mg) increased by 0.07 - 0.18 mEq/L after the start of treatment with SGLT2 inhibitors [3, 4]. The EMPA-REG OUTCOME study also showed that serum Mg increased from 1.7 to 1.8 mEq/L [1].…”

Section: To the Editormentioning

confidence: 99%

Is an Increase in Serum Magnesium One of the Causes of Cardiovascular Events Reduction in the EMPA-REG OUTCOME Study?

Yanagawa

2017

J Clin Med Res

View full text Add to dashboard Cite

“…Previous studies have demonstrated elevation of the serum Mg concentrations after the initiation of SGLT-2 inhibitor treatment [12]. We recently suggested that the increase of the serum Mg level associated with SGLT2 inhibitor treatment could explain, at least in part, the reduction of the CV risk observed in the EMPA-REG OUTCOME study [13], because, as mentioned above, hypomagnesemia increases the risk of CV events.…”

Section: Mg Concentration Increases With Sglt2 Inhibitor Treatmentmentioning

confidence: 84%

“…This rapid effect of the drug is difficult to explain based on the beneficial effects of empagliflozin on the glucose and lipid metabolism alone, which are of much slower onset. Various hypotheses have been proposed, and while the precise mechanism(s) remain unknown, the ketone body hypothesis and hematocrit hypothesis have attracted the most attention [11].Previous studies have demonstrated elevation of the serum Mg concentrations after the initiation of SGLT-2 inhibitor treatment [12]. We recently suggested that the increase of the serum Mg level associated with SGLT2 inhibitor treatment could explain, at least in part, the reduction of the CV risk observed in the EMPA-REG OUTCOME study [13], because, as mentioned above, hypomagnesemia increases the risk of CV events.…”

mentioning

confidence: 99%

Is the Renoprotective Effect of SGLT2 Inhibitors due to their Beneficial Effect on Hypomagnesemia?

Yanagawa¹

2017

J Diabetes Metab

View full text Add to dashboard Cite

Magnesium (Mg) deficiency is linked to diabetes and cardiovascular (CV) events. Treatment with the sodiumglucose cotransporter 2 (SGLT2) inhibitor was associated with a suppressed occurrence of CV events in patients with type 2 diabetes. We recently suggested that the increase of the serum Mg level associated with SGLT2 inhibitor treatment could explain, at least in part, the reduction of the CV events. Recently SGLT2 inhibitors have also been reported to exert a renoprotective effect and various hypotheses have been proposed regarding the mechanism. Now we would like to propose another possible mechanism, namely, the role of Mg.Keywords: Magnesium; Sodium-glucose cotransporter 2 inhibitor; Diabetic nephropathy; Renoprotection Magnesium Deficiency is linked to Diabetes, Hypertension and Cardiovascular EventsMagnesium (Mg) acts as a coenzyme in the insulin secretion pathway, influences the insulin sensitivity, and acts as a modulator of Na-K ATPase. Insufficient intake of Mg can cause diabetes [1] and hypertension.Mg exerts favorable effects on the cardiovascular (CV) system, including an anti-inflammatory effect on the vascular endothelium and smooth muscle, vascular relaxant activity, and sympatholytic activity [2]. Of the total Mg content of the body, 99% is present within the cells, and only 1% is present outside cells. Thus, while hypomagnesemia reflects Mg deficiency in the whole body, Mg deficiency could be present even in the presence of serum Mg levels within the normal range [3]. Subjects with hypomagnesemia are known to be at an elevated risk of developing CV disease [4]. According to the findings of the Framingham Heart Study, hypomagnesemia is a risk factor for atrial fibrillation [5]; hypomagnesemia has also been reported to be associated with a risk of premature ventricular contractions, particularly in diabetic patients [6]. In addition, animal experiments have shown that hypomagnesemia causes reduced cardiac function [7]. Furthermore, hypomagnesemia has been reported to increase platelet aggregation, thereby facilitating thrombus formation, and to enhance coronary artery constriction, thereby increasing the risk of development of myocardial infarction [2].A high incidence of CV events and sudden death has also been reported in patients with hypomagnesemia. A meta-analysis of relevant studies, even those including patients without diabetes, revealed that elevation of the serum Mg level by 0.2 mmol/L was associated with a 30% decrease in the risk of onset of CV disease and 40% decrease in the risk of death from CV events [8]. Adequate dietary magnesium intake has been reported to be associated with a reduced risk of cardiovascular events [9]. Thus, it might be reasonable to conclude that the risk of CV disease/events decreases as the serum Mg concentration increases. Mg Concentration Increases with SGLT2 Inhibitor TreatmentSodium-glucose cotransporter 2 (SGLT-2) is expressed in the proximal renal tubules, where it reabsorbs about 80-90% of the filtered glucose. Selective and reversible inhi...

show abstract

Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials

Cited by 110 publications

References 28 publications

Serum Magnesium Level of Newly Detected Patients with Glucose Intolerance and Its Comparison with Serum Magnesium Level of Age and Sex Matched Healthy Volunteers

Serum Magnesium Level of Newly Detected Patients with Glucose Intolerance and Its Comparison with Serum Magnesium Level of Age and Sex Matched Healthy Volunteers

Is an Increase in Serum Magnesium One of the Causes of Cardiovascular Events Reduction in the EMPA-REG OUTCOME Study?

Is the Renoprotective Effect of SGLT2 Inhibitors due to their Beneficial Effect on Hypomagnesemia?

Contact Info

Product

Resources

About